Business
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding t
About this update from Invivyd, Inc.
[{"type":"image","alt":"Invivyd","displaySize":"","headline":null,"caption":"Invivyd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MyR5b2vdhRgALtKrzLKLAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy ","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work demonstrating similar relationships from the pandemic era","length":329,"tagName":"p"}]},{"val":[{"type":"text","content":"Model-derived estimates align with observed infection outcomes and external analyses including work with prior Invivyd and other COVID mAbs, supporting model validity and variant-agnostic protection from COVID across multiple Invivyd antibodies","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"Analysis highlights the predictability of clinical efficacy from drugging stable epitopes, irrespective of SARS-CoV-2 virus variation outside drug epitope, and predicts meaningful protection at low overall monoclonal antibody levels","length":232,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1045,"olType":false},{"type":"text","content":"NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of Invivyd’s monoclonal antibody pemivibart to predict clinical protection levels from COVID purely from laboratory-determined serum monoclonal antibody activity levels, irrespective of virus variation. This newly published analysis builds on similar, earlier peer...